IP Library Granted Patent US 11,344,607
Granted Patent B2
US 11,344,607 · App. 15/759,060 · Granted May 31, 2022

Treatment of disease with relaxin

Inventors: Roy Garvin (Glasgow, GB); Alasdair Burns (Glasgow, GB)
Assignee: BV BIOMED LTD
A61K38/2221A61K31/565A61K45/06A61P25/00A61P25/02A61P29/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,344,607
App. No.
15/759,060
Granted
May 31, 2022
Kind
B2
Abstract

The present invention relates to relaxin or a homologue or variant thereof for use in a method of treating an inflammatory condition, for example an autoimmune inflammatory condition. The invention also relates to the treatment of an inflammatory condition, for example an autoimmune inflammatory condition comprising administering to a subject in need thereof a relaxin, or a homologue or variant thereof. Such conditions may be CNS conditions or be organ specific.

Claims (3)

1. A method of treating traumatic spinal cord injury comprising administering an effective amount of relaxin selected from human relaxin 1 and relaxin 2, a homologue selected from prorelaxin and preprorelaxin or variant thereof to a subject in need thereof, wherein the relaxin, the homologue or the variant thereof is a polypeptide, wherein the variant thereof has at least 95% similarity or identity to the relaxin or the homologue, and wherein administration of the relaxin, the homologue or the variant thereof reduces the levels of IL-6 and IL-17 in the spinal cord and brain, reduces demyelination, preserves neurofilaments, protects neurons, and stops or reverses gliosis.

2. The method according to claim 1 , wherein the method further comprises the administration of estrogen.

3. The method according to claim 1 , wherein the variant thereof has at least 98% similarity or identity to the relaxin or the homologue.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2020
From: BVBIOMED LTD
To: BVBIOMEDICAL LIMITED
Reel/Frame 053504/0028 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2018
From: GARVIN, ROY; BURNS, ALASDAIR
To: BV BIOMED LTD
Reel/Frame 045162/0037 →
Priority Claims (1)
GB 1516068 · Sep 10, 2015 · national
Continuity (1)
Related Publication 20190000927A1 · Jan 3, 2019
Cited By (2)
US 12,264,188 US 12,509,497